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Objectives: Cefazolin is a commonly prescribed β-lactam antibiotic for prophylaxis against skin infections
following surgery, including caesarean sections. Assessment of maternal and neonatal exposure is
important for correlating drug concentrations to clinical outcomes. Thus, bioanalytical methods for the
quantiﬁcation of both total and free cefazolin in maternal plasma and cord blood can assist in the
comprehensive evaluation of cefazolin exposure.
Design and methods: Specimen preparation for the measurement of total cefazolin was performed via
protein precipitation with acetonitrile containing the internal standard cloxacillin. Ultraﬁltration was used to
isolate free cefazolin. Processed samples were analyzed on a Prelude SPLC system coupled to a TSQ triple
quadrupole Vantage mass spectrometer. Methods were validated following FDA bioanalytical guidelines.
Results: The analytical measuring ranges of these methods were 0.48–480 mg/mL and 0.048–48 mg/mL for
total and free drug, respectively. Calibration curves were generated using 1/x2 weighted linear regression
analysis. Total cefazolin demonstrated inter- and intra-assay precision of r20% at the LLOQ and r11.2% at
other levels. Free cefazolin demonstrated inter- and intra-assay precision of r18.5% at the LLOQ and r12.6%
at other levels, respectively. Accuracy (%DEV), carryover, matrix effects, recovery and stability studies were
also acceptable based on FDA recommendations. Furthermore, it was demonstrated that samples prepared in
cord blood can be accurately quantiﬁed from an adult plasma calibration curve, with recoveries r9.1% DIF
and r11.9% DIF for total and free cefazolin, respectively.
Conclusions: The described LC–MS/MS methods allow for the measurement of total and free cefazolin in
both plasma and cord blood.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cephalosporin antibiotics have become one of the most commonly prescribed classes of β-lactams due to their broad spectrum of anti-
bacterial activity, low toxicity proﬁle, and ease of administration [1,2]. Consequently, cephalosporins have been utilized for the treatment
of a number of soft tissue and skin infections in both perioperative and post-surgical settings, particularly as prophylactic agents [1,3–5].
Cephalosporins are semi-synthetic compounds initially derived from the fungus Cephalosporium acremonium [6]. Structurally, these drugs
are comprised of a β-lactam moiety fused to a 3,6-dihydro-2H-1,3-thiazine ring [1]. There are several generations of cephalosporin
antibiotics, and family members are stratiﬁed based on their anti-bacterial activity and route of administration.
Cefazolin, a ﬁrst-generation cephalosporin, is widely used to manage skin infections, and has also shown therapeutic efﬁcacy in the
treatment of pulmonary infections and methicillin-susceptible Staphylococcus aureus [7,8]. Like other ﬁrst-generation cephalosporins,
cefazolin is effective in treating Gram-positive bacteria, but does not elicit equally effective bactericidal effects against Gram-negative
bacteria [6,9]. Moreover, cefazolin has been administered prophylactically to prevent post-surgical skin infections, including those
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incurred during cesarean deliveries [10,11]. Cesarean delivery is the primary risk factor for postpartum maternal infections caused by
Gram-positive bacteria, and studies have demonstrated that the infection rate in a post-cesarean setting can be as high as 38% [12].
Notably, the prophylactic administration of cefazolin prior to skin incision reduced post-cesarean morbidity as well as endometritis, and
has been recommended by the American College of Obstetrics and Gynecology as a perioperative prophylactic agent during cesarean
deliveries [11–13]. While the majority of the drug is predominantly protein bound by albumin (90% bound), cefazolin elicits its
antimicrobial effects in the unbound, or free, form [14–16]. Thus, determination of both total and free cefazolin concentrations may be
helpful in better characterizing the pharmacokinetics of the cephalosporin in a variety of clinical scenarios, including in a post-cesarean
setting. Cefazolin quantiﬁcation in the mother, as well as the neonate, can provide clarity on neonatal drug exposure, as well as its
potential impact on post-delivery outcomes, including the prevention of neonatal sepsis [17]. Neonatal drug exposure measurement has
been assessed in many matrices including urine, blood, meconium, hair, and umbilical cord blood. Umbilical cord blood is a convenient
matrix to assess neonatal exposure because it should reﬂect recent changes in neonatal exposure at the time of delivery without having to
perform a venipuncture.
Cefazolin quantiﬁcation has been previously reported using high performance liquid chromatographic (HPLC) [18–20] or liquid
chromatographic–tandem mass spectrometric (LC–MS/MS) [21–25] approaches. However, none of the aforementioned methods have
extensively evaluated the acceptability of cord blood as a matrix for cefazolin determination. While several methods provide strategies for
directly quantifying free drug concentration, only the methods published by Zhang et al. [21] and Douglas et al. [23] utilized tandem mass
spectrometry as an analytical detector [18–20,22]. Here we present a comprehensive method describing the development and validation
of LC–MS/MS methods for the quantiﬁcation of total and free cefazolin via ultraﬁltration in plasma and cord blood. The method uses a low
volume of specimen for determination, requiring less than 250 mL for determination of both total cefazolin and free drug within a sample.
2. Materials and methods
2.1. Chemicals
Cefazolin (97% purity) as its sodium salt, its structural analogue cloxacillin (94% purity) as its hydrated sodium salt (Fig. 1), and
ethylenediaminetetraacetic acid (EDTA) were acquired in powder form from Sigma Aldrich (St. Louis, MO). Drug-free human K2EDTA
plasma was purchased from Biological Specialty Corporation (Colmar, PA). Drug-free human K2EDTA cord blood plasma was purchased
from Golden West Biologicals (Temecula, CA). HPLC-grade water, acetonitrile, and formic acid were acquired from Fisher Scientiﬁc
(Pittsburgh, PA).
2.2. Preparation of reagents and standards
Concentrations of cefazolin and cloxacillin are presented as their free base forms. Cefazolin working solutions for preparation of
calibration standards were prepared for determination of total cefazolin by initially preparing a solution containing 23,800 mg/mL
cefazolin in 1:1 acetonitrile:water by weighing standard material and diluting volumetrically. Working solutions were prepared at ﬁnal
concentrations of 48 mg/mL, 480 mg/mL, and 4,800 mg/mL via serial dilution of the initial stock solution. Calibration standards were
prepared at ﬁnal concentrations of 0.48, 2.4, 4.8, 12, 24, 48, 120, 240, and 480 mg/mL by spiking K2EDTA plasma with the appropriate stock
solution. The concentrations reﬂect the quantity of the cefazolin sodium salt in solution. Total organic volume added to plasma was o2%.
Quality control (QC) materials were prepared using working solutions prepared from an independent weighing from the solutions used to
prepare calibration standards. Working solutions for preparation of QC materials were prepared at concentrations of 190, 2400, and
48,000 mg/mL in 1:1 acetonitrile:water. Working solutions for the preparation of QC materials were diluted into K2EDTA plasma at ﬁnal
concentrations of 0.48 (lower limit of quantiﬁcation, LLOQ), 1.4 (low QC), 18.0 (mid QC), and 410 (high QC) mg/mL.
Cefazolin working solutions for preparation of calibration standards were prepared for the determination of free cefazolin by initially
preparing a solution of 1900 mg/mL cefazolin in 1:1 acetonitrile:water by weighing standard material and diluting volumetrically. Working
Fig. 1. Structures of (A) the beta-lactam antibiotic cefazolin and its (B) structural analog, cloxacillin.
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solutions were prepared at ﬁnal concentrations of 0.19 mg/mL, 19 mg/mL, and 190 mg/mL via serial dilution. Calibration standards were
prepared at ﬁnal concentrations of 0.048, 0.095, 0.24, 0.48, 0.95, 2.4, 4.8, 9.5, 24, and 48 mg/mL by spiking K2EDTA plasma ultraﬁltrate with
the appropriate stock solution. QC materials were prepared from working solutions prepared independently from solutions for
preparation of calibration standards. A working stock of 1900 mg/mL was prepared by weighing standard material and diluting
volumetrically, and subsequent working stock solutions were prepared as previously described. These working solutions were used to
prepare QC materials in plasma ultraﬁltrate at ﬁnal concentrations of 0.048 (LLOQ), 0.14 (low QC), 1.8 (mid QC), and 41 (high QC) mg/mL.
Internal standard solutions were prepared in HPLC grade acetonitrile for total cefazolin determination and HPLC grade water for free
cefazolin determination at ﬁnal concentrations of 9.2 mg/mL and 1.8 mg/mL, respectively, by diluting a 1.8 mg/mL stock solution that was
prepared by weighing cloxacillin and diluting it volumetrically using 50% acetonitrile.
2.3. Sample preparation
2.3.1. Total cefazolin
Total cefazolin concentrations in plasma and cord blood were determined after samples had been subjected to protein precipitation.
Twenty microliters of calibrator or QC was diluted 1:50 with acetonitrile at ambient temperature containing 9.2 mg/mL cloxacillin in a
Fisherbrand 1.5 mL polypropylene microcentrifuge tube (Waltham, MA; ﬁnal cloxacillin concentration of 9.0 mg/mL). This mixture was
vortexed for 5 min using a Scientiﬁc Industries Vortex Genie 2 (Bohemia, New York). After mixing, samples were centrifuged at 17,921 x g
for 5 min using an Eppendorf 5415D microcentrifuge (Hamburg, Germany). One-hundred microliters of supernatant was diluted four-fold
with HPLC grade H2O in a Nunc 96 DeepWell 2 mL polypropylene plate (Rochester, NY) and loaded onto the instrument for analysis.
During the development of this assay, we compared drug recovery from samples prepared in borosilicate tubes and Nunc deepwell plates.
We noticed comparable recovery (495%) between the borosilicate tubes and deepwell plates (data not shown). The injection volume was
10 μL for downstream LC–MS/MS analysis.
2.4. Free cefazolin
Free cefazolin concentrations in plasma and in cord blood were determined after samples had been treated using an ultraﬁltration
technique. Two-hundred microliters of plasma was loaded onto a Corning SPIN-X UF 500 μL 10 k MW cutoff concentrator device (Corning, NY)
and centrifuged at 1646 x g for 30 min to produce an ultraﬁltrate. Twenty microliters of ultraﬁltrate, or 20 μL of calibrators or QC materials
previously prepared in ultraﬁltrate from blank plasma, were diluted 1:50 with HPLC H2O at ambient temperature containing 1.9 mg/mL
cloxacillin in a Fisherbrand 1.5 mL polypropylene microcentrifuge tube (Waltham, MA; ﬁnal cloxacillin concentration of 1.8 mg/mL).
This mixture was brieﬂy vortexed using a Scientiﬁc Industries Vortex Genie 2. Four-hundred microliters of this mixture was loaded into
Nunc 96 DeepWell 2 mL polypropylene plate and loaded onto the instrument for analysis. The injection volume was 10 μL for downstream
LC–MS/MS analysis.
Bulk plasma ultraﬁltrate for preparation of standards and QC materials was prepared using a single lot of human plasma using large
capacity ﬁltration devices identical in composition to those prepared for individual specimen preparation (Corning SPIN-X UF 20 mL
capacity 10 k MW cutoff concentration devices). Plasma was added to spin devices and centrifuged at 1645 x g for 30 min using a Thermo
Scientiﬁc Jouan C4i swinging bucket centrifuge (San Jose, CA). Ultraﬁltrate was pooled from collections and used in the preparation of the
calibrators and QC materials.
2.5. Instrument and acquisition parameters
Chromatographic separation was performed on the Thermo Scientiﬁc Prelude SPLC system (San Jose, CA) operating in laminar only
mode (LX). Specimens were maintained at 4 1C in a CTC PAL autosampler (Carrboro, NC). Cefazolin and its structural analog were
chromatographically separated using a Phenomenex Kinetex C8 (502.1 mm2, 1.7 mm particle size) column (Torrance, CA) maintained at
40 1C. The mobile phase system consisted of water containing 2% acetonitrile and 0.1% formic acid (mobile phase A, MPA) and acetonitrile
containing 0.1% formic acid (mobile phase B, MPB). A third solvent consisting of 45:45:10 acetonitrile:isopropanol:acetone was introduced
to the analytical column during the wash step. To reduce carryover, 10 μL of 1 mM EDTA was injected into the injection port and ﬂowed
through the column between analyses. Full chromatographic conditions are listed in Table 1. The total method time was 5 min.
Detection was performed on a Thermo TSQ Vantage triple quadrupole mass spectrometer (San Jose, CA) using a heated electrospray
ionization source and operated in positive ionization mode with nitrogen sheath gas supplied by a Parker-Balston N2-80 nitrogen
generator (Haverhill, MA). The detection window was from 0.5 to 2.5 min of the chromatographic run. Collision cell gas was ultra-high
purity argon supplied by Airgas (Radnor, PA). The electrospray source was operated under the following conditions, which was optimized
for cefazolin product ion generation: spray voltage 4500 V, vaporizer temperature 200 1C, sheath gas pressure 30, aux gas pressure 35, and
capillary temperature 200 1C. Quantiﬁer transitions for cefazolin and cloxacillin were 455 -156m/z (collision energy (CE): 15 eV) and
437-278m/z (CE: 14 eV), respectively. Qualiﬁer transitions for cefazolin and cloxacillin were 455-323m/z (CE: 9 eV) and 437-160m/z
(CE: 15 eV), respectively.
2.6. Data evaluation
XCalibur 2.2 software (Thermo Scientiﬁc) was used for data acquisition and processing. Calibration curves were generated using linear
regression with 1/x2 weighting and peak areas generated after Gaussian smoothing using the Genesis integration algorithm. Microsoft
Ofﬁce Excel 2010 was used to determine coefﬁcients of variation. Outliers were identiﬁed using the Grubb's test for outliers. Carryover
effects were evaluated using EP Evaluator Release 8 (Data Innovations, South Burlington, VT). Figures were prepared using ACD/
ChemSketch, R, and Inkscape.
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Coefﬁcient of variation (%CV) is deﬁned below, where σ is the standard deviation and x is the average concentration observed.
%CV¼ σ
x
 100 ð1Þ
%DEV is deﬁned below, where xExpected is the theoretical concentration of the QC material, and xObserved is the average concentration
determined for a QC material by solving for its concentration using the aforementioned regression equation relating peak area ratio to
calibrator concentration.
%DEV¼ xObserved xExpected
 
xExpected
 100 ð2Þ
%DIF is deﬁned below, where xRef erence is the average measured concentration of the QC material in a reference condition, and xTreated is the
average concentration measured for the same level QC material treated differently.
%DIF¼ xTreated xRef erence
 
xRef erence
 100 ð3Þ
%ME, %PE, and %RE are presented as relative recoveries, where x1 is the average determined peak area intensity for a reference treatment
for a component (cefazolin or cloxacillin) determined from a QC material and x2 is the average area intensity test treatment for a QC
material. For example, in determining cefazolin matrix effects, x1 is the average area intensity for cefazolin in unextracted preparation and
x2 is the average area intensity for cefazolin in post-extracted material.
%ME; %PE; %RE¼ x2
x1
 100 ð4Þ
3. Method validation
The LC–MS/MS methods were validated based on FDA Guidance for Industry: Bioanalytical Method Validation recommendations [26].
Validation metrics included intra- and inter-assay precision and accuracy, linearity, stability, carryover, and matrix effects. These
parameters were fully characterized for total cefazolin in human plasma. Free cefazolin was validated in human plasma ultraﬁltrate by
addressing precision, accuracy, and carryover. Cord blood was evaluated by measuring recovery of cefazolin in cord blood and cord blood
ultraﬁltrate spiked with cefazolin from a calibration curve prepared in non-cord blood plasma.
3.1. Precision and accuracy
Intra-assay precision was determined by replicate injection (n¼6) of total or free cefazolin QC materials at four levels. Observed means,
SDs and %CVs were assessed at each level. The LLOQ was deﬁned as the lowest calibrator on the calibration curve, and in accordance with
FDA recommendations, yielded accuracy and precision criteria of r20%DEV from theoretical concentrations and imprecision of r20%CV.
Targets for levels above the LLOQ were r15%DEV from theoretical concentrations and imprecision of r15%CV. Total cefazolin QC
materials were prepared at the lower limit of quantiﬁcation (LLOQ; 0.48 mg/mL), low (1.4 mg/mL), mid (18 mg/mL) and high (410 mg/mL)
concentrations in plasma by spiking stock solutions into plasma. Free cefazolin QC materials were set at LLOQ (0.048 mg/mL), low (0.14 mg/mL),
mid (1.8 mg/mL) and high (41 mg/mL) concentrations in plasma ultraﬁltrate. Inter-assay precision was determined by evaluating the
observed concentrations for each level from three separate analytical runs and sample preparations, which is consistent with FDA
recommendations. Concentrations determined were those generated from the calibration curve performed on each run.
3.2. Carryover
Carryover was determined by alternating injections of low (L) concentration calibrator (either 0.48 or 0.048 mg/mL for cefazolin or free
cefazolin, respectively) and high (H) concentration calibrator (either 410 or 41 mg/mL for cefazolin or free cefazolin, respectively) and
comparing the mean concentration of the low calibrators injected prior to high calibrator to those injected after. Speciﬁcally, calibrators
were injected in the order: L1, L2, L3, H1, H2, L4, H3, H4, L5, L6, L7, L8, H5, H6, L9, H7, H8, L10, H9, H10, and L11. Acceptability criteria were
mean post-high injection levels o3SD greater than pre-high injection levels. These acceptability criteria are consistent with CLSI protocol
EP10-A2 [27]. Moreover, during routine analysis, injections of solvent A (0.1% formic acid) were injected following injection of the highest
concentration calibrator. Acceptability criterion was post-injection blank signal, measured as chromatographic peak area o20% of the
signal observed for the lowest concentration calibrator.
Table 1
Chromatographic conditions for the determination of cefazolin and free cefazolin.
Step Start time (min) Flow rate (mL/min) %A %B Gradient
1 0 0.5 95 5 Step
2 0.5 0.5 5 95 Linear ramp
3 2.5 0.5 5 95 Step
4 3.0 0.05þ0.75 Wash 5 95 Step
5 3.5 0.5 95 5 Linear ramp
6 3.75 0.5 95 5 Step
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3.3. Stability
Stability studies were conducted for total cefazolin analysis. Low, mid, and high QC levels were subjected to injection matrix stability,
sample matrix stability, and freeze–thaw stability. Injection matrix stability experiments were conducted by re-analyzing QC extracts
maintained at 4 1C four days after preparation by re-analyzing calibrators and QC materials, quantifying on the basis of the new calibration
curve, and comparing to the original values. Sample matrix stability experiments were conducted by analyzing quality control materials
after incubating for 24 h at room temperature. Freeze–thaw stability experiments were conducted by comparing freshly compared quality
control material to material that had undergone n¼4 freeze–thaw cycles using a freezer maintained at 20 1C. Stock stability experiments
were conducted where stock solution was incubated at room temperature, 4 1C, and 20 1C for 3 weeks. Acceptability was determined as
r±15%DIF from the signal acquired from the material that had been stored at 20 1C.
3.4. Matrix effects
Matrix effects studies were conducted for total cefazolin analysis. Matrix effects on ionization were assessed using methods previously
described by Matuszewski and colleagues [28] using sets of QC materials prepared at low, mid, and high concentrations. These materials
were prepared for analysis in three independent sets: unextracted, pre-extracted, and post-extracted. Brieﬂy, unextracted samples were
prepared using the described protocol but substituting MPA (0.1% formic acid) in place of plasma, pre-extracted samples containing QC
levels spiked into plasma from six individual lots, and a post-extracted set, which involved the addition of a spiking solution into post-
extracted plasma matrix from the aforementioned six independent lots. The ﬁnal concentrations at low, mid and high QCs were
maintained across all three sets. The raw peak area values generated by these analyses were compared to calculate matrix effects, recovery
efﬁciency, and processing efﬁciency. Individual set %CVs were also determined. Matrix effects were evaluated by the recovery ratio of post-
extracted:unextracted; recovery efﬁciency was evaluated by the recovery ratio of pre-extracted:post-extracted; processing efﬁciency was
evaluated by the recovery ratio of pre-extracted:unextracted.
3.5. Cord blood comparison
The described LC–MS/MS method was also used to assess drug quantiﬁcation of total cefazolin in cord blood and free cefazolin in cord
blood ultraﬁltrate, respectively. Acceptability of quantifying drug concentrations in cord blood from an adult human plasma (non-cord
blood) calibration curve was determined by calculating %DIF of low, mid, and high QC levels as compared to adult plasma QC material
analyzed on the same calibration curve. Cefazolin working solutions for the preparation of QC materials for total and free cefazolin were
used to generate equivalent concentration materials in both cord blood plasma and plasma ultraﬁltrate. Cord blood plasma ultraﬁltrate
was prepared using the same protocol for determination of free cefazolin: brieﬂy, Corning ultraﬁltration devices were implemented for the
ﬁltration of 200 mL sample. A pool of ultraﬁltrate was generated for the preparation of QC materials. Cord blood materials were prepared at
the same low, mid, and high QC concentrations as prepared for total and free cefazolin determination. Acceptability limits were deﬁned as
r±15%DIF from material prepared in human plasma or human plasma ultraﬁltrate; this acceptability threshold has been implemented for
stability-challenged samples, and was thus applied when comparing plasma and cord blood results.
4. Results and discussion
4.1. Liquid chromatographic–tandem mass spectrometric (LC–MS/MS) parameters
Cefazolin was chromatographically separated from matrix components under a gradient elution proﬁle with a Phenomenex Kinetex C8
column (Table 1 and Fig. 2). Using the described method, cefazolin and cloxacillin eluted at 1.5 and 2.0 min, respectively. The Phenomenex
Kinetex C8 column is a sub-2 mm porous particle column that lends itself to clinical applications because of fast, sharp peaks and moderate
back pressure [29]. Due to the lack of availability of isotopically labeled cefazolin, a β-lactam structural analogue, cloxacillin, was used as an
internal standard. Other methods described for cefazolin analysis also used structural analogues as internal standards [23–25]. Acetonitrile
was chosen as mobile phase B as it demonstrated higher ionization efﬁciency than methanol (data not shown). The addition of EDTA into
the injection port in line with the column, as well as introduction of a strong wash solvent during the wash step, was used in this method
to mitigate carryover; during initial stages of development, carryover was observed to be 1–2% of the signal intensity area of the high
concentration material. This carryover was eliminated after replicate injections of blank mobile phase A (Fig. 3). This observation,
combined with the necessity to achieve an appropriately dynamic analytical measuring range (AMR), resulted in the subsequent
modiﬁcations to the LC method. The strong wash solvent was introduced using a second binary pump with a switching valve and a tee into
the analytical column.
Optimized ionization source and mass spectrometry parameters for cefazolin and cloxacillin were determined by manually adjusting
conditions during direct infusion. Both compounds were analyzed in their protonated [MþH]þ forms. Selected reaction monitoring (SRM)
mode ion transitions were selected on the basis of signal intensity and imprecision during suitability experiments. Moreover, though the
molecular formula of these fragment ions was not conﬁrmed with labeling studies, their masses indicate they are not products of common
losses (condensation, decarboxylation, etc.) and may contain the tetrazole ring, which is the characteristic R2 moiety for cefazolin.
Chromatograms generated from qualiﬁer ion transitions were evaluated on the basis of their peak shape. Application of qualiﬁer
transitions is especially important when utilizing a structural analogue as an internal standard for quantitative mass spectrometry. One
major consequence of a structural analogue as an internal standard is that it often does not co-elute with the analyte. Potential
interferences may cause ion suppression and signiﬁcantly affect the accuracy of results.
The method published by Douglas et al. used in vivo microdialysis to determine free cefazolin concentrations, which is impractical for
routine clinical testing [23]. The method published by Zhang et al. presented a relatively comprehensive validation for determining total
and free cefazolin in human plasma, but did not provide details on comparative studies in cord blood, nor did it provide details on
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improving analytical selectivity through the introduction of a qualiﬁer ion transition [21]. Evaluation of qualiﬁer ion transitions adds
additional analytical speciﬁcity to a mass spectrometry method because interferences may have differential efﬁciency at producing signals
for different ion transitions. Cord blood, while not an independent matrix, was validated in terms of precision and accuracy studies to
assess any potential interferents on drug quantiﬁcation and to better characterize the overall ruggedness of the analytical method. This
method was validated using FDA Bioanalytical Method Validation guidelines because it is a well-established set of guidelines suitable for
pharmacokinetic studies, which will be the primary application for the assay.
Ultraﬁltration was chosen to isolate the free fraction of cefazolin because it is rapid, relatively inexpensive to implement on a limited
study scale, and only requires a microcentrifuge, which is commonly available in a clinical research laboratory. The internal standard was
added to the ultraﬁltrate of processed material because the addition of material prior to ﬁltration would disrupt the equilibrium of the
system. As a result, we used standard ﬁltration conditions, particularly those designed to ﬁlter albumin, to sample the free fraction of
cefazolin using ultraﬁltration. The topic in general has been evaluated in the literature, particularly in the application of free phenytoin
determination by immunoassay following ultraﬁltration [30].
4.2. Precision, accuracy and calibration curve analysis
Intra- and inter-assay precision and accuracy for total cefazolin and free cefazolin were determined following the recommendations of
the FDA guidelines as previously described (Table 2). Total cefazolin intra-assay precision ranged from 6.2% to 20.0%CV at the LLOQ. Intra-
assay accuracy as %DEV ranged from 4.3% to 14.8%. Total cefazolin inter-assay precision ranged from 6.2% to 19.1% at the LLOQ. Inter-
assay accuracy as %DEV ranged from 7.7% to 11.9%. Free cefazolin intra-assay precision ranged from 7.2% to 17.8% at the LLOQ. Free
cefazolin intra-assay accuracy ranged from 6.7% to 3.4%. Free cefazolin inter-assay precision ranged from 5.7% to 18.5% and inter-assay
deviation ranged from 1.9% to 2.5%. All observed results were acceptable for all QC levels.
The AMRs of the assays were 0.48–480 mg/mL for total cefazolin and 0.048–48 mg/mL for free cefazolin (Fig. 4 and data not shown). The
AMRs are sufﬁciently dynamic and encompass typical cefazolin concentrations observed following standard dosing, as total cefazolin
plasma concentrations typically achieve levels 1.4–141 mg/mL [22]. The AMR was expanded 3-fold beyond this limits to account for
unexpected over-dosing, under-dosing, as well as studies that adjust the timing of dosing. Standard dosing protocols include 1–2 g
Fig. 2. Representative chromatograms for (A) cefazolin LLOQ, low QC and blank plasma and (B) cloxacillin internal standard and blank plasma.
Fig. 3. Representative chromatograms of carryover optimization sequences. Chromatograms from (A) are prior to optimization. Chromatograms from (B) are post-
optimization.
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cefazolin t.i.d. for treatment of infections or 1–2 g single dose for prophylaxis during surgery [2,31,32]. The analytical measuring range of
unbound cefazolin spans 1 order of magnitude less than the analytical measuring range for total cefazolin; this is consistent with plasma
protein binding resulting in free concentrations 10% of total concentrations [33]. Both assays utilized standard curves constructed using
1/x2 weighted linear regressions of the peak area ratio of cefazolin and cloxacillin relative to the cefazolin concentration of calibrators.
The standard curve intercepts and linear coefﬁcients were used to determine total cefazolin and free cefazolin concentrations in quality
control materials and unknown specimens. The average correlation coefﬁcient R2 for regression ﬁttings was Z0.99 (Fig. 4). The upper
limit of quantiﬁcation was determined by observing the highest concentration that provided a linear calibration curve, in this method that
concentration (480 or 48 mg/mL for total cefazolin and free cefazolin) provided an analytical measuring range of three orders of
magnitude. The upper end of the calibration curve does appear to slightly under-recover, as reﬂected by the high QC bias of 7.7%, but this
small value was still within the acceptability criterion deﬁned by FDA Bioanalytical Method Validation guidelines. Adoption of an
isotopically labeled internal standard of cefazolin may mitigate this bias.
4.3. Carryover
Carryover analysis was conducted according to CLSI guidelines by evaluating the determined average concentration of low
concentration standards injected in alternating series with high concentration standards [27]. Overcoming issues with carryover was
critical during method development because of the broad dynamic range of the method. Carryover was not noticed when observing
analogous signal of the cloxacillin internal standard, suggesting potential accumulation of cefazolin in the SPLC system at high
concentrations. Based on these observations, a stringent wash of 45:45:10 acetonitrile:2-propanol:acetone was introduced during the
wash step as well as introducing EDTA into the injection port post-sample injections. These additional steps were relatively facile to
implement as the EDTA could be added to a well in the 96-well plate used for specimen preparation and the stringent wash step was easy
to introduce by using a union instead of a turboﬂow column in the TX position of the SPLC. The addition of these steps greatly reduced
carryover (Fig. 3). In order to continuously monitor carryover, injection sequences were programmed to inject blank MPA (0.1% formic
acid) after the highest concentration calibrator (480 or 48 mg/mL cefazolin for total cefazolin and free cefazolin, respectively). After
introduction of the stringent wash and post-injection EDTA bolus we did not experience any issues with carryover during assay validation.
Table 2
Inter-assay and intra-assay precision and accuracy.
QC level Concentration (mg/mL) Intra-assay precision and accuracy Inter-assay precision and accuracy
Mean (mg/mL) SD (mg/mL) %CV %DEV Mean (mg/mL) SD (mg/mL) %CV %DEV
Total cefazolin
LLOQ 0.48 0.547 0.110 20.0 14.8 0.534 0.102 19.1 11.9
Low 1.4 1.52 0.171 11.2 6.5 1.49 0.151 10.1 4.4
Mid 18 18.7 1.93 10.3 4.7 18.7 1.49 8.0 4.6
High 410 388 23.9 6.2 4.3 374 23.3 6.2 7.7
Free cefazolin
LLOQ 0.048 0.0445 0.00790 17.8 6.7 0.0467 0.00650 18.5 1.1
Low 0.14 0.145 0.0147 10.1 1.1 0.140 0.0176 12.6 1.9
Mid 1.8 1.79 0.186 10.4 0.0 1.83 0.153 8.4 2.5
High 41 41.9 3.01 7.2 3.4 41.3 2.33 5.7 1.9
Fig. 4. Representative calibration curves for total cefazolin analysis. The y-axis of (A) is the peak area ratio observed between cefazolin and cloxacillin quantiﬁer transitions.
The y-axis of (B) is the calculated concentration using linear regression.
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The observed signal of a post-injection blank following a high QC sample was o2% of the signal observed at the LLOQ, indicating the
successful abrogation of carryover.
4.4. Stability
Stability studies were conducted to evaluate cefazolin stability in injection matrix, sample matrix, and after serial freeze–thaw cycles
(Table 3). Injection matrix stability was evaluated after allowing extracts to incubate at 4 1C for four days in the autosampler prior to
injection and comparison to freshly prepared quality control material. Percent differences from this experiment ranged from 4.4% to
2.7%. Sample matrix stability was evaluated by allowing a control material to thaw and sit at room temperature for 24 h prior to processing
and analysis. Comparison of these samples to freshly thawed and analyzed samples yielded percent differences ranging from 15.0% to
2.7%. Freeze–thaw stability was evaluated by comparing recovery of QC material that had undergone n¼4 freeze–thaw cycles prior to
analysis relative to quality control material prepared fresh. Comparison of these samples to freshly thawed and analyzed samples yielded
percent differences ranging from 11.2% to 7.3%. The recovery determined in these experiments was within acceptable criteria (r±15%
DIF). However, the freeze–thaw cycle data all indicate negative differences, which suggest some instability of the analyte to sustain
free–thaw cycles, leading to degradation.
4.5. Selectivity and matrix effects
No peaks were observed near the retention times for cefazolin or cloxacillin in blank plasma (Fig. 2). Moreover, six independent lots of
human plasma were evaluated in the process and showed no interfering peaks (data not shown). Matrix effects were evaluated by
comparing peak area signals generated from cefazolin spiked into water (unextracted) and processed according to the protocol, cefazolin
spiked into plasma and processed according to protocol (pre-extracted), or spiked into blank plasma extract (post-extracted). Matrix
effects are determined by comparing the apparent signal from post-extracted material to unextracted material. The recovery efﬁciency for
matrix effects at low, mid, and high QC levels ranged 88.5–106.6% for cefazolin and 91.7–98.9% for cloxacillin (Table 4). At each QC level,
there is less than 10% difference in overall matrix effects between cefazolin and cloxacillin, further supporting the use of cloxacillin as an
internal standard. Recovery efﬁciency was determined by comparing the peak area intensities of pre-extracted material to post-extracted
material. These recoveries ranged from 74.6% to 87.9% for cefazolin and 101.4% to 107.6% for cloxacillin. It is expected for recovery of
cefazolin to be less than that of cloxacillin as cefazolin must be isolated from the plasma matrix, whereas the internal standard is in
solvent. Processing efﬁciency was evaluated by comparing pre-extracted material to un-extracted material. The recoveries ranged from
68.7% to 93.7% for cefazolin and 93% to 106% for cloxacillin. The overall processing efﬁciency for cefazolin reﬂects the minimal matrix
effects seen in addition to the decreased recovery from plasma. However, as there are no relative matrix effects and cefazolin
concentrations are determined by the peak area ratio of drug to internal standard, the method may be used for cefazolin quantiﬁcation.
4.6. Cord blood comparison
In lieu of full validation by preparing calibration and quality control material sets in cord blood, we validated its acceptability as a
specimen matrix by evaluating recovery of cefazolin spiked directly into cord blood or cord blood ultraﬁltrate. These concentrations were
determined using calibration curves generated using total cefazolin calibrators in human plasma or free cefazolin calibrators in human
plasma ultraﬁltrate for total cefazolin and free cefazolin, respectively. The values determined from the cord blood plasma quality control
materials were compared to the values determined from plasma and plasma ultraﬁltrate. The difference from the two values was
calculated and a %DIF was determined, with an acceptability criteria of r±15%. The relative recovery for cefazolin in cord blood and cord
blood ultraﬁltrate ranged 4.9% to 9.1% for total cefazolin and 1.4% to 11.9% for free cefazolin (Table 5). These values were within our
limit of acceptability of r±15%DIF. These results suggest that cord blood plasma and cord blood plasma ultraﬁltrate may be analyzed
alongside plasma and plasma ultraﬁltrate specimens using the aforementioned conditions described in the protocol. This is the ﬁrst
demonstration verifying acceptability for analysis of both total and free cefazolin in plasma and plasma ultraﬁltrate as well as cord blood
plasma and cord blood plasma ultraﬁltrate.
The described LC–MS/MS methods facilitate the quantiﬁcation of total and free cefazolin in both adult and cord blood plasma. These
methods take advantage of convenient ultraﬁltration techniques for separating the free drug from plasma proteins. The methods are fast
at 5 min per analysis and only require 20 μl of plasma for determination of total cefazolin and 200 μl of plasma for determination of free
cefazolin. However, there are some limitations to the described methods. The steps required to achieve satisfactory carryover performance
with additional wash steps that could be prohibitive if the HPLC does not easily facilitate introduction of strong wash solvent during an
analysis. Another limitation is the necessity of consuming an ultraﬁltration device for assessing free cefazolin concentrations. The free
cefazolin method uses standard ultraﬁltration conditions to remove plasma proteins, but the calibrators and quality control materials were
prepared directly in plasma ultraﬁltrate. Ideally, a method would utilize well-characterized materials of known free drug concentration as
calibrators and quality controls. Additionally, alternative methods to ultraﬁltration, such as rapid equilibrium dialysis, may reduce the
amount of technician time required for analysis. Moreover, these methods have not been compared to a reference laboratory due to a lack
Table 3
Cefazolin stability studies.
QC Level Freeze–thaw cycle, n¼6 Sample matrix stability, n¼6 Injection matrix stability, n¼6
Control mean Treated mean %DIF Control mean Treated mean %DIF Control mean Treated mean %DIF
Low (1.4 mg/mL) 1.54 1.39 9.7 1.53 1.34 15.0 1.54 1.47 0.8
Mid (18 mg/mL) 17.9 16.6 7.3 18.1 18.1 2.7 17.9 18.8 2.7
High (410 mg/mL) 388 345 11.2 388 350 9.8 379 362 4.4
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of testing availability. Lastly, we have not evaluated the described methods in a patient cohort; this will be performed in forthcoming
studies.
5. Conclusions
A rugged LC–MS/MS method for the quantiﬁcation of total and free cefazolin in both adult and cord blood plasma has been developed
and validated.
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